ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - USD ($)	1 Months Ended	3 Months Ended		6 Months Ended
	Jul. 31, 2023	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022
Liquidity and Capital Resources
Revenue		$ 16,074,000	$ 594,000	$ 23,877,000	$ 2,610,000
Accumulated deficit		1,613,875,000		1,613,875,000		$ 1,527,033,000
BRIUMVI (Ublituximab)
Liquidity and Capital Resources
Revenue				23,800,000,000
Cash and cash equivalents, and investment securities		$ 144,900,000		$ 144,900,000
Neuraxpharm Agreement
Liquidity and Capital Resources
Amount of one-time, non-refundable payment upon contract execution	$ 140,000,000.0